Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients.

De Giorgi V, Savarese I, D'Errico A, Gori A, Papi F, Colombino M, Sini MC, Grazzini M, Stanganelli I, Rossari S, Covarelli P, Massi D, Palmieri G.

Pigment Cell Melanoma Res. 2015 Nov;28(6):747-51. doi: 10.1111/pcmr.12403. No abstract available.

PMID:
26223839
2.

Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.

Potrony M, Puig-Butille JA, Aguilera P, Badenas C, Tell-Marti G, Carrera C, Javier Del Pozo L, Conejo-Mir J, Malvehy J, Puig S.

JAMA Dermatol. 2016 Apr;152(4):405-12. doi: 10.1001/jamadermatol.2015.4356.

3.

CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.

Majore S, De Simone P, Crisi A, Eibenschutz L, Binni F, Antigoni I, De Bernardo C, Catricalà C, Grammatico P.

Pigment Cell Melanoma Res. 2008 Apr;21(2):209-11. doi: 10.1111/j.1755-148X.2008.00446.x. Epub 2008 Mar 18. No abstract available.

PMID:
18363633
4.

High incidence of primary melanomas in an MC1R RHC homozygote/CDKN2A mutant genotype patient.

Sinnya S, Jagirdar K, De'Ambrosis B, McMeniman E, Sturm RA, Soyer HP.

Arch Dermatol Res. 2015 Oct;307(8):741-5. doi: 10.1007/s00403-015-1582-y. Epub 2015 Jun 24.

PMID:
26103950
5.

The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H, Begg CB; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1520-5.

6.

Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?

Pollio A, Tomasi A, Seidenari S, Pellacani G, Rodolfo M, Frigerio S, Maurichi A, Turchetti D, Bassoli S, Ruini C, Ponti G.

Pigment Cell Melanoma Res. 2013 Sep;26(5):755-7. doi: 10.1111/pcmr.12122. Epub 2013 Jun 27. No abstract available.

PMID:
23802662
7.

Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.

Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA.

Genes Chromosomes Cancer. 2008 Feb;47(2):175-84.

PMID:
18023021
8.

Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.

Mantelli M, Pastorino L, Ghiorzo P, Barile M, Bruno W, Gargiulo S, Sormani MP, Gliori S, Vecchio S, Ciotti P, Sertoli MR, Queirolo P, Goldstein AM, Bianchi-Scarrà G; Italian Melanoma Intergroup.

Melanoma Res. 2004 Dec;14(6):443-8.

PMID:
15577313
9.

Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S.

J Am Acad Dermatol. 2014 Nov;71(5):888-95. doi: 10.1016/j.jaad.2014.06.036. Epub 2014 Jul 24.

10.

Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.

Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA.

J Invest Dermatol. 2008 Aug;128(8):2122-5. doi: 10.1038/jid.2008.51. Epub 2008 Mar 13. No abstract available.

11.

Histologic features of melanoma associated with CDKN2A genotype.

Sargen MR, Kanetsky PA, Newton-Bishop J, Hayward NK, Mann GJ, Gruis NA, Tucker MA, Goldstein AM, Bianchi-Scarra G, Puig S, Elder DE.

J Am Acad Dermatol. 2015 Mar;72(3):496-507.e7. doi: 10.1016/j.jaad.2014.11.014. Epub 2015 Jan 13.

12.

Estimating the relative risk of developing melanoma in INK4A carriers.

Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady MS, Roy P, Song Y, Canchola R, Barz A, Halpern A, Bolognia J, Eng S, Elahi A, Begg CB.

Eur J Cancer Prev. 2004 Feb;13(1):65-70.

PMID:
15075790
13.

Clinical genetic testing for familial melanoma in Italy: a cooperative study.

Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, Leachman SA, Bianchi Scarrà G; IMI, Italian Melanoma Intergroup.

J Am Acad Dermatol. 2009 Nov;61(5):775-82. doi: 10.1016/j.jaad.2009.03.039. Epub 2009 Jun 4.

PMID:
19500876
14.

CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Abate Osella S, Bernengo MG, Bianchi Scarrà G.

Pigment Cell Melanoma Res. 2008 Dec;21(6):700-9. doi: 10.1111/j.1755-148X.2008.00512.x. Epub 2008 Oct 22.

PMID:
18983535
15.

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G.

J Am Acad Dermatol. 2016 Feb;74(2):325-32. doi: 10.1016/j.jaad.2015.09.053.

PMID:
26775776
16.

CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.

Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J.

Cancer Res. 2000 Dec 15;60(24):6864-7.

17.

Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.

Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L; French Familial Melanoma Study Group, Bressac-de Paillerets B, Avril MF, Demenais F.

J Am Acad Dermatol. 2012 Dec;67(6):1257-64. doi: 10.1016/j.jaad.2012.05.014. Epub 2012 Jul 26.

PMID:
22841127
18.

Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.

Stratigos AJ, Yang G, Dimisianos R, Nicolaou V, Stefanaki I, Katsambas AD, Tsao H.

J Invest Dermatol. 2006 Feb;126(2):399-401.

19.

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Lund Melanoma Study Group; Melanoma Genetics Consortium (GenoMEL).

J Med Genet. 2007 Feb;44(2):99-106. Epub 2006 Aug 11.

20.

Pediatric melanoma in melanoma-prone families.

Goldstein AM, Stidd KC, Yang XR, Fraser MC, Tucker MA.

Cancer. 2018 Sep 15;124(18):3715-3723. doi: 10.1002/cncr.31641. Epub 2018 Sep 12.

Supplemental Content

Support Center